Dissemination of Patient-Centered Outcomes Research in Hepatitis C Virus to Infec
Dissemination of Patient-Centered Outcomes Research in Hepatitis C Virus to Infec
批准号:
8810682
负责人:
David L Thomas
金额:
$9.21万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-01 至 2016-01-31
中文摘要
描述(由申请人提供):1传播丙型肝炎以患者为中心的结果研究-2背景:在美国,估计有近400万人感染3型丙型肝炎病毒(丙型肝炎病毒),每年约有20,000例新感染病例。1,2,4卫生和公共服务部发布了一项预防、护理和治疗病毒性肝炎的行动计划,旨在提高人们对这种“沉默的流行病”的认识,6减少新的丙型肝炎感染病例的数量,所有这些都与健康人2020 7目标一致。iii最近对8项筛查成本效益的研究支持了一个主要的回应,这项研究导致疾控中心制定了新的丙型肝炎筛查指南,要求对1945-1965年出生的每个人进行9项检测。这些新的指南预计将在今年晚些时候发布,并将显著增加对丙型肝炎病毒的识别。11 AHRQ已经编写了几篇互补性综述,重点是丙型肝炎病毒的筛查、治疗、12和坚持治疗。向身份证专家迅速传播这一信息是下一个关键步骤,但需要资源才能及时有效地做到这一点。14本计划提案的总体目标是通过扩大身份证提供者的能力来识别和治疗16例丙型肝炎病毒感染,从而降低与丙型肝炎病毒感染相关的发病率和死亡率。为了实现这一目标,IDSA的丙型肝炎工作组将开发17个教育方案和资源,以协助ID专家和研究员诊断、管理和治疗病毒性肝炎。具体地说,工作队将(1)以自我评估知识模块的形式对ID专家进行深入培训;(2)为ID研究员提供20次培训,重点是21种丙型肝炎的流行病学、诊断、管理和治疗,大大扩大了他们可以通过培训计划获得的培训;以及22(3)向初级保健社区提供外联,以推广丙型肝炎筛查指南和23与诊断后护理的联系。24这项提议将直接支持实现与丙型肝炎病毒有关的2020年健康人目标25中的两个目标--提高感染者认识的目标和减少新感染人数的目标26。考虑到丙型肝炎病毒领域迅速变化的时机,以及国际开发协会已被证明有能力通过教育活动影响其成员的28种做法模式,如本提案中计划的29项具体措施,成功的可能性很高。我阿姆斯特朗GL,华斯莱A,西马德EP,麦克奎兰总经理,库纳特WL,改变MJ。1999年至2002年美国丙型肝炎病毒感染的流行情况。《安实习生医学》2006;144:705-14。美国疾病控制与预防中心。急性病毒性肝炎监测--美国,2008年。可在以下网址获得:http://www.cdc.gov/hepatitis/Statistics/2008Surveillance/index.htm.三、抗击无声的病毒性肝炎流行:预防、护理和治疗病毒性肝炎的行动计划。卫生与公众服务部。2011年5月12日。于2012年1月17日在http://www.hhs.gov/ash/initiatives/hepatitis访问
英文摘要
DESCRIPTION (provided by applicant): 1 Dissemination of HCV Patient-Centered Outcomes Research - 2 Background: In the United States, nearly 4 million persons are estimated to be infected with 3 hepatitis C virus (HCV) with approximately 20,000 newly infected cases occurring each year.i,ii 4 Department of Health and Human Services has issued an action plan for the prevention, care 5 and treatment of viral hepatitis which aims to raise awareness of this "silent epidemic" and 6 reduce the number of new HCV infection cases, all in alignment with the Healthy People 2020 7 objectives.iii One major response is supported by recent research into the cost-effectiveness of 8 screening that has led the CDC to formulate new HCV screening guidelines that will call for the 9 testing of every person born 1945-1965. These new guidelines are expected to be released 10 later this year and will markedly increase HCV identification. 11 AHRQ has produced several complementary reviews focused on HCV screening, treatment, 12 and adherence to therapy. The rapid dissemination of this information to ID specialists is the 13 next critical step but requires resources to do so in a timely and effective manner. 14 The overarching goal of this program proposal is to reduce the morbidity and mortality 15 associated with HCV infection by expanding the capacity of ID providers to identify and treat 16 HCV infection. In order to achieve this goal, the IDSA's Hepatitis C Task Force will develop 17 educational programs and resources to assist ID specialists and fellows in the diagnosis, 18 management, and treatment of viral hepatitis. Specifically, the task force will (1) develop in- 19 depth training for ID specialists in the form of self-evaluation knowledge modules; (2) provide 20 training for ID fellows focused on the epidemiology, diagnosis, management, and treatment of 21 HCV, significantly expanding that which they may receive through their training programs; and 22 (3) provide outreach to the primary care community to promote HCV screening guidelines and 23 linkage to care following diagnosis. 24 This proposal will directly support the achievement of two of the Healthy People 2020 goals 25 related to hepatitis C virus - the goal of increasing the awareness of those infected and the goal 26 of decreasing the number of new infections. There is a high likelihood of success given the 27 timing of the rapid changes in the field of HCV and proven capability of IDSA to impact the 28 practice patterns of their membership through educational activities such as the specific 29 measures planned in this proposal. i Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-14. ii CDC. Surveillance for acute viral hepatitis-United States, 2008. Available at: http://www.cdc.gov/hepatitis/Statistics/2008Surveillance/index.htm. iii Combating the Silent Epidemic of Viral Hepatitis: Action Plan for Prevention, Care and Treatment of Viral Hepatitis. Department of Health & Human Services. May 12, 2011. Accessed on January, 17, 2012 at http://www.hhs.gov/ash/initiatives/hepatitis
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma
-
批准号:10259887
-
项目类别:
-
资助金额:$35.09万
-
财政年份:2020
-
负责人:David L Thomas
-
依托单位:
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma
-
批准号:10689175
-
项目类别:
-
资助金额:$35.13万
-
财政年份:2020
-
负责人:David L Thomas
-
依托单位:
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma
-
批准号:10471416
-
项目类别:
-
资助金额:$36.08万
-
财政年份:2020
-
负责人:David L Thomas
-
依托单位:
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma
-
批准号:10084616
-
项目类别:
-
资助金额:$28.27万
-
财政年份:2020
-
负责人:David L Thomas
-
依托单位:
HIV HCV Coinfection Antiviral Therapy and Fibrosis
-
批准号:9066124
-
项目类别:
-
资助金额:$72.62万
-
财政年份:2015
-
负责人:David L Thomas
-
依托单位:
HIV HCV Coinfection Antiviral Therapy and Fibrosis
-
批准号:8915844
-
项目类别:
-
资助金额:$73.36万
-
财政年份:2015
-
负责人:David L Thomas
-
依托单位:
Dissemination of Patient-Centered Outcomes Research in Hepatitis C Virus to Infec
-
批准号:8464492
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2013
-
负责人:David L Thomas
-
依托单位:
GB VIRUS C INFECTION OF MACAQUES: AN HIV VACCINE MODEL
-
批准号:7349792
-
项目类别:
-
资助金额:$5.73万
-
财政年份:2006
-
负责人:David L Thomas
-
依托单位:
GB VIRUS C INFECTION OF MACAQUES: AN HIV VACCINE MODEL
-
批准号:7165343
-
项目类别:
-
资助金额:$4.8万
-
财政年份:2005
-
负责人:David L Thomas
-
依托单位:
Clinical Core
-
批准号:7014312
-
项目类别:
-
资助金额:$26.42万
-
财政年份:2005
-
负责人:David L Thomas
-
依托单位:
GB VIRUS C INFECTION OF MACAQUES: AN HIV VACCINE MODEL
-
批准号:6971611
-
项目类别:
-
资助金额:$1.37万
-
财政年份:2004
-
负责人:David L Thomas
-
依托单位:
The Progression of Hepatitis C Among IDUs
-
批准号:6588695
-
项目类别:
-
资助金额:$71.36万
-
财政年份:2002
-
负责人:David L Thomas
-
依托单位:
The Progression of Hepatitis C Among IDUs
-
批准号:7883675
-
项目类别:
-
资助金额:$74.31万
-
财政年份:2002
-
负责人:David L Thomas
-
依托单位:
The Progression of Hepatitis C Among IDUs
-
批准号:7285807
-
项目类别:
-
资助金额:$70.81万
-
财政年份:2002
-
负责人:David L Thomas
-
依托单位:
The Progression of Hepatitis C Among IDUs
-
批准号:6778307
-
项目类别:
-
资助金额:$75.38万
-
财政年份:2002
-
负责人:David L Thomas
-
依托单位:
The Progression of Hepatitis C Among IDUs
-
批准号:7653805
-
项目类别:
-
资助金额:$73.19万
-
财政年份:2002
-
负责人:David L Thomas
-
依托单位:
The Progression of Hepatitis C Among IDUs
-
批准号:7083156
-
项目类别:
-
资助金额:$6.5万
-
财政年份:2002
-
负责人:David L Thomas
-
依托单位:
The Progression of Hepatitis C Among IDUs
-
批准号:7455930
-
项目类别:
-
资助金额:$71.26万
-
财政年份:2002
-
负责人:David L Thomas
-
依托单位:
The Progression of Hepatitis C Among IDUs
-
批准号:7086384
-
项目类别:
-
资助金额:$68.59万
-
财政年份:2002
-
负责人:David L Thomas
-
依托单位:
The Progression of Hepatitis C Among IDUs
-
批准号:8097512
-
项目类别:
-
资助金额:$72.34万
-
财政年份:2002
-
负责人:David L Thomas
-
依托单位:
海外基金